Sunshine Heart Implants First Patient in COUNTER HF US Pivotal Trial

Sunshine Heart, Inc. (NASDAQ: SSH ) announced today the first patient implant in the Company's U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III